The combination of Pembrolizumab (PD-1 inhibitor) and Lenvatinib (tyrosine kinase inhibitor) is approved by the Food and Drug Administration (FDA) for the treatment of mismatch repair–proficient (pMMR) endometrial cancer who have relapsed to at least one line of cytotoxic chemotherapy [13–15]. This evidence concerns the gene PDCD1 and endometrial cancer.